Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct-Dec;7(4):488-93.
doi: 10.4103/0974-7796.158507.

Significance of p53 and ki-67 expression in prostate cancer

Renuka Verma  1 , Veena Gupta  1 , Jagjeet Singh  2 , Monica Verma  3 , Gopal Gupta  4 , Sumiti Gupta  1 , Rajeev Sen  1 , Megha Ralli  1
Affiliations

Significance of p53 and ki-67 expression in prostate cancer

Renuka Verma et al. Urol Ann. 2015 Oct-Dec.

Abstract

Background: Prostate cancer is a major health problem throughout the developed world. Tumor grade is one of the most important prognostic factors of prostate cancer. At present, adequate prognostic markers for prostate cancer progression are still lacking, in spite of intensive investigation. Accordingly, we studied the role of immunohistochemical (IHC) expression of p53 and Ki-67 as a prognostic factor in carcinoma prostate and correlated their expression with Gleason's grade.

Materials and methods: In this prospective study, a total of 60 cases including 50 cases of prostate carcinoma and 10 of benign prostatic hyperplasia (BPH) were taken. Tumor grade was determined according to Gleason's grading system. p53 and Ki-67 expressions were determined by IHC staining. The obtained results were analyzed and evaluated using Spearman's statistical test (SPSS version 20).

Results: In BPH, p53 was expressed in only 2 of 10 (20%) cases while in carcinoma it was expressed in 38 of 50 (76%) cases. Ki-67 was expressed in only 1 of 10 (10%) BPH cases while in carcinoma it was expressed in 32 of 50 (64%) cases. In present study, 1 of 4 (25%) well differentiated, 23 of 31 (74.19%) moderately differentiated and 14 of 15 (93.33%) poorly differentiated tumors revealed p53 immunopositivity and a statistically significant correlation was observed between p53 expression and increased Gleason's grade (P = 0.038). All 4 (100%) cases of well-differentiated carcinoma were negative for Ki-67 expression. Nineteen of 31 (61.29%) moderately differentiated and 13 of 15 (86.66%) poorly differentiated tumors were positive for Ki-67 and a statistically significant correlation was observed between Ki-67 positivity and increased Gleason's grade (P = 0.002).

Conclusions: Both p53 and Ki-67 were significantly up-regulated in malignant lesions as compared to benign lesions and a strong relationship with the Gleason's grading was noticed, therefore, we propose that these markers can be applied along with other prostate cancer prognostic factors.

Keywords: Gleason's grade; Ki-67 (MIB-1); p53; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None.

Figures

Figure 1
Figure 1
(a) Well differentiated prostatic carcinoma showing p53 positivity (grade 1) (immunohistochemical [IHC], ×200) and (b) absence of Ki-67 expression (IHC, ×200)
Figure 2
Figure 2
Moderately differentiated prostatic carcinoma showing p53 positivity (grade 3) (immunohistochemical [IHC], ×200) (b) Ki-67 positivity (index 3+) (IHC, ×200)
Figure 3
Figure 3
Poorly differentiated prostatic carcinoma showing p53 positivity (grade 3) (immunohistochemical [IHC], ×200) and (b) Ki-67 positivity (index 3+) (IHC, ×200)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer; 2013. [Last accessed on 2014 Jul 20]. Available from: http://globocan.iarc.fr.[Internet]
    1. Epstein JI. The lower urinary tract and male genital system. In: Kumar V, Abbas AK, Fausto N, editors. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia: Saunders; 2010. pp. 993–1002.
    1. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 2010;24:1967–2000. - PMC - PubMed
    1. Madani SH, Ameli S, Khazaei S, Kanani M, Izadi B. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer. Indian J Pathol Microbiol. 2011;54:688–91. - PubMed
    1. Moul JW, Gaddipati J, Srivastava S. Molecular biology of prostate cancer: Oncogenes and tumor suppressor genes. In: Dawson NA, Vogelzang NJ, Srivastava S, editors. Current Clinical Oncology: Prostate Cancer. New York: Wiley-Liss; 1994. pp. 19–46.